Ophthalmology | Novartis

Featured News
Oct 13, 2022
World Sight Day 2022: Raising awareness on the importance of eye health
Media Release
Mar 31, 2022
Novartis announces European Commission approval of Beovu® for people living with diabetic macular edema
Media Release
Dec 22, 2021
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
Media Release
Oct 13, 2021
Novartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edema
Featured News
Oct 14, 2021
World Sight Day 2021
Story
Oct 13, 2021
Restoring vision and hope to thousands in Southeast Asia
Media Release
Aug 17, 2021
Novartis announces positive results from Phase III trials of Beovu® in diabetic macular edema, including dosing intervals up to 16 weeks
Media Release
Sep 21, 2021
Novartis übernimmt Arctos Medical und erweitert damit ihr Optogenetik-Portfolio, um Patientinnen und Patienten mit einem schwerem Verlust des Sehvermögens Gentherapien anbieten zu können
Media Release
Sep 21, 2021
Novartis acquiert Arctos Medical, élargissant ainsi son portefeuille d’optogénétique afin de proposer des thérapies géniques aux patients souffrant d’une sévère perte de la vision
Media Release
Sep 21, 2021
Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss
Media Release
Sep 14, 2020
Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
Media Release
Sep 14, 2020
European Medicines Agency (EMA) approves safety label update for Novartis Beovu®